Non-aqueous suspensions of antibodies are much less viscous than equally concentrated aqueous solutions

Pharmaceutical Research

Volumn 30, Issue 7, 2013, Pages 1749-1757

  Srinivasan, Charudharshini ^a   Weight, Alisha K ^a   Bussemer, Till ^b   Klibanov, Alexander M ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Biologics Center   (Germany)

Author keywords

amorphous; formulation; proteins; suspension; viscosity

Indexed keywords

ALCOHOL; BOVINE IMMUNOGLOBULIN; MONOCLONAL ANTIBODY;

AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; PARTICLE SIZE; POWDER; PRIORITY JOURNAL; SUSPENSION; TEMPERATURE; VISCOSITY;

ANIMALS; ANTIBODIES, MONOCLONAL; CATTLE; ETHANOL; GAMMA-GLOBULINS; MICE; SALTS; SOLUTIONS; SURFACE-ACTIVE AGENTS; SUSPENSIONS; VISCOSITY; WATER;

EID: 84878883303     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1017-4     Document Type: Article

References (25)

1. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nature Revs Immunol. 2010;10:345-52.
2. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Revs Immunol. 2010;10:317-27.
3. Ahamed T, Esteban BNA, Ottens M, van Dedem GWK, van der Wielen LAM, Bisschops MAT, et al. Phase behavior of an intact monoclonal antibody. Biophys J. 2007;93:610-9. (Pubitemid 47057825)
4. Yang MX, Shenoy B, Disttler M, Patel R, McGrath M, Pechenov S, et al. Crystalline monoclonal antibodies for subcutaneous delivery. Proc Natl Acad Sci U S A. 2003;100:6934-9. (Pubitemid 36706371)
5. Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J Pharm Sci. 2004;93:1390-402. (Pubitemid 38725014)
6. Du W, Klibanov AM. Hydrophobic salts markedly diminish viscosity of concentrated protein solutions. Biotechnol Bioeng. 2011;108:632-6.
7. Guo Z, Chen A, Nassar RA, Helk B, Mueller C, Tang Y, et al. Structure-activity relationship for hydrophobic salts as viscosity-lowering excipients for concentrated solutions of monoclonal antibodies. Pharm Res. 2012;29:3102-9.
8. Miller MA, Engstrom JD, Ludher BS, Johnston KP. Low viscosity highly concentrated injectable nonaqueous suspension of lysozyme microparticles. Langmuir. 2010;26:1067-74.
9. Johnston KP, Maynard JA, Truskett TM, Borwankar AU, Miller MA, Wilson BK, et al. Concentrated dispersion of equilibrium protein nanoclusters that reversibly dissociate into active monomers. ACS Nano. 2012;6:1357-69.
10. Basu SK, Govardhan CP, Jung CW, Margolin AL. Protein crystals for the delivery of biopharmaceuticals. Expert Op Biol Ther. 2004;4:301-17. (Pubitemid 38352127)
11. He F, Becker GW, Litowski JR, Narhi LO, Brems DN, Razinkov VI. High throughput dynamic light scattering methods for measuring viscosity of concentrated protein solutions. Anal Biochem. 2010;399:141-3.
12. Krieger IM, Dougherty TJ. A mechanism for non-Newtonian flow in suspensions of rigid spheres. Trans Soc Rheol. 1959;3:137-52.
13. Patel AR, Kerwin BA, Kanapuram SR. Viscoelastic characterization of high concentration antibody formulations using quartz crystal microbalance with dissipation monitoring. J Pharm Sci. 2009;98:3108-16.
14. Kanai S, Liu J, Patapoff HW, Shire SJ. Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity. J Pharm Sci. 2008;97:4219-27.
15. Yadav S, Shire SJ, Kalonia DS. Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. J Pharm Sci. 2010;99:4812-29.
16. Patel HM, Kraszewski JL, Mukhopadhyay B. The phosphoenolpyruvate carboxylase from Methanothermobacter thermautotrophicus has a novel structure. J Bacteriol. 2004;186:5129-37. (Pubitemid 38970839)
17. Englard S, Seifter S. Precipitation techniques. Meth Enzymol. 1990;182:285-300. (Pubitemid 20154395)
18. Matheus S, Friess W, Schwartz D, Mahler H-C. Liquid high concentration IgG1 antibody formulations by precipitation. J Pharm Sci. 2009;98:3043-57.
19. Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nature Revs Drug Discov. 2005;4:298-306. (Pubitemid 41130943)
20. Van Oss CJ. On the mechanism of the cold ethanol precipitation method of plasma protein fractionation. J Protein Chem. 1989;8:6661-8. (Pubitemid 20036122)
21. Klibanov AM. Improving enzymes by using them in organic solvents. Nature. 2001;409:241-6. (Pubitemid 32144293)
22. Foster TP, Moseley WM, Caputo JF, Alaniz GR, Leatherman MW, Yu X, et al. Sustained elevated serum somatotropin concentrations in Holstein steers following subcutaneous delivery of a growth hormone releasing factor analog dispersed in water, oil or microspheres. J Control Rel. 1997;47:91-9. (Pubitemid 27154404)
23. FDA. Inactive ingredient search for approved drug products. November 23, 2012. Available from: http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm.
24. Bowen M, Armstrong N, Ma Y-F. Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection. J Pharm Sci. 2012;101:4433-43.
25. Dai W, Hill B, Liu K, Mieczkowski C. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies. US Patent Application 2012; 0 076 800.